Cytek Biosciences Inc (CTKB)
Debt-to-capital ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — |
| Total stockholders’ equity | US$ in thousands | 393,064 | 425,546 | 405,385 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $393,064K)
= 0.00
The debt-to-capital ratio of Cytek Biosciences Inc has remained constant at 0.00 for the past three years, indicating that the company has not utilized any debt to finance its operations relative to its total capital structure. This implies that Cytek Biosciences relies primarily on equity financing to support its business activities. While a debt-to-capital ratio of 0.00 may suggest financial stability and low financial risk, it is essential to consider the potential implications of a lack of debt in terms of tax benefits, financial flexibility, and overall cost of capital. Further analysis of Cytek Biosciences' capital structure and financial strategy would provide deeper insights into the company's financing decisions and risk management practices.
Peer comparison
Dec 31, 2023